ABOUT VELICEPT

Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS).

PIPELINE

Solabegron has completed and demonstrated positive results in initial Phase II clinical studies for the treatment of overactive bladder (OAB) in women and irritable bowel syndrome (IBS). Solabegron has completed and demonstrated positive results in initial Phase II clinical studies for the treatment of overactive bladder (OAB) in women and irritable bowel syndrome (IBS). Solabegron is currently being studied in 2 phase 2b studies evaluating both BID and novel QD formulations.

NEWS + EVENTS

Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent

-Additional Funding to Advance Phase 2b Development Program in OAB- -Enrollment for Second Phase 2 Study Well Underway- -Issuance of U.S. Patent No. 10,065,922 Further Expands Velicept’s Portfolio Covering Solabegron- MALVERN, Pa.–(BUSINESS WIRE)–Velicept Therapeutics, a privately-held clinical stage pharmaceutical company dedicated to the development of best-in-class compounds for the treatment of urological and gastrointestinal disorders, […]